PNAS breakthrough: Antimalarial drugs promise to treat deadly brain cancer!

May 28, 2020 /PRNewswire
BIOON/-GBM, a polymorphic glioblastoma is an invasive brain cancer, often fatalBut the new findings by researchers at Virginia State University's Massey Cancer Center (VCU) Massey Cancer Center and the Institute of Molecular Medicine (VIMM) may help increase the effectiveness of the most common treatment available today, the addition of benzoyl alcohol, a drug approvedFDAfor malariaWhile current treatment standards include radiotherapy and tamoxetine, an anti-cancer chemotherapy drug, that slightly extend the lives of patients with polyglioma, GBM resistance to these treatments is commonIn addition, the five-year survival rate of GBM patients treated by the standard of care is less than 6%, and no treatment is currently available to prevent recurrenceresearchers have been working on the redevelopment
FDAapproved drugs and rarer drugs that may help fight drug resistance and therapeutic effects of glioblastoma"Our study reveals a possible new application of this antimalarial drug as a treatment for multiple glial mothercell tumors that are resistant to radiation therapy and tamoxamine therapyDrPaul BFisher saidThe study was recently published in the Proceedings of the National Academy of Sciences image source: https://cn.bing.com
in particular, benzene alcohol inhibits a gene element associated with the development of cancer, Fli-1, which controls the resistance of polymorphic glioblastoma to radiotherapy and tamoxamine in in vitro studies (conducted with cultured cells), researchers found that adding benzene alcohol to treatment for glioblastoma can kill cancer cells and inhibit tumor cell growth This occurs in cells where glioblastoma cells are sensitive and resistant to radiation and tamoxamine In addition, in in vivo studies (transplanting a human polyploid colloidal glioblastoma in the brains of mice), benzene alcohol inhibited the growth of tumors caused by the treatment of sensitive and resistant glioblastoma cells
tumors researchers have identified the resistance of Fli-1-mediated cancer cells to the treatment by genetic and molecular techniques, and this finding that benzoyl alcohol inhibits cell resistance has become the focus of current research The researchers found that "heat shock protein B1", also known as HSPB1, was regulated by Fli-1 in glioblastoma The innovative screening strategy of Fli-1 inhibitors identified phenylalcohol as a drug that is expected to bind to Fli-1 and inactivate it, thereby inhibiting the expression of important genes that regulate the growth, survival and cancer of polysaccotic melanoma, which causes tumor in addition, , extracellular matrix (ECM) reconstruction and epithelial protozoa transformation (EMT) are two key processes to tumor invasion and diffusion, and are important factors in regulating the response and resistance of glioblastoma to radiotherapy and chemotherapy These two processes are regulated by Fli-1 and inhibited by benzene alcohol to help treat glioblastoma, researchers will further explore other ways to combat Fli-1-induced therapeutic resistance "These preclinical studies provide a solid theoretical basis for benzoyl alcohol inhibition of Fli-1/HSPB1 and a potential new approach to the treatment of glioblastoma," Fisher said The identification of drugs such as phenylalcohol from FDA
-approved treatments provides an opportunity to expand the scope and versatility of current treatment options for patients with multiple glioblastomas In addition to glioblastoma, high expression of Fli-1 can also be seen in cancers such as melanoma, ovarian cancer, breast cancer , suggesting that blocking Fli-1 may also help other cancer patients, the researchers said "The current results may be broader than just treating glioblastoma," Fisher said (BioValleyBioon.com) References: Anti-malarial drug show show for brain cancer Yetirajam Rajesh et al, Lumefantrine, an antimalarial drug, reverse radiation and temozolomide resistance in the of the National Academy of Sciences (2020) DOI: 10.1073/pnas.1921531117